Heart, blood and circulation

442 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Heart, blood and circulation
Treatment and conditionWhere it standsTrials
"Trained Eye" (Angiography-Guided) LM PCI for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
1 Stent for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
2 Stents for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AAV2/8-HLP-FVIII-V3 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abatacept for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Acetylcysteine for st elevation myocardial infarctionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Albipagrastim alf for febrile neutropeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Alpelisib for lymphatic abnormalitiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amiodarone for heart arrestPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amrecibart for atrial fibrillationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Amrecibart for thrombosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Amrecibart for venous thromboembolismPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 1 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 2 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 3 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Antithrombin iii human for antithrombin iii deficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apixaban for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apixaban for thrombosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Arm 1: treatment with Shockwave Reducer for angina pectorisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aroxxen for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ascorbic Acid for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aspirin for purpura, thrombotic thrombocytopenicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ASTX727 for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
ATO + Ascorbic acid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for myocardial infarctionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Autoinjector + EVOLOCUMAB for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for hematologic diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Avacopan for vasculitisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Ascorbic Acid for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Azacitidine + Ascorbic Acid for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 + Posaconazole for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Baxdrostat for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Benralizumab for hypereosinophilic syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for beta-thalassemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezuclastinib for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BiOSS LIM C for coronary artery diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
BiOSS LIM C for coronary stenosisTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
BiVACOR TAH System for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Placebo for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bread with added beta-glucans for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brentuximab vedotin for hematologic diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CagriSema for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Calf Plantar flexion + Dietary nitrate for peripheral arterial diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Canakinumab for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Canakinumab for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovalve TR valve replacement System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carvedilol for heart failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cenvacibart for atrial fibrillationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Cenvacibart for thrombosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Cenvacibart for venous thromboembolismPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cholecalciferol for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CID-103 for purpuraPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CIPROFLOXACIN + Ceftazidime for febrile neutropeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clazakizumab for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clazakizumab for hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clopidogrel for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clopidogrel for angina, stableTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clopidogrel for myocardial infarctionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Colchicine for acute coronary syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine for coronary diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine for myocardial infarctionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine for myocarditisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for atherosclerosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for coronary diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for heart diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg + Usual Care Group for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combined antioxidant therapy for myocardial reperfusion injuryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Combined antioxidant therapy for st elevation myocardial infarctionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Control for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Coronary Sinus Reducer for angina pectorisTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Coronary Sinus Reducer for angina, stableTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Coronary Sinus Reducer for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Coronary Sinus Reducer for microvascular anginaTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Crizanlizumab for anemia, sickle cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CSL222 (AAV5-hFIXco-Padua) for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danicopan for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin + Empagliflozin for heart failure, systolicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin propanediol for heart failure, systolicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Darbepoetin alfa + canakinumab for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
DCD Heart Transplantation Using NRP for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
DIAG723 for telangiectasia, hereditary hemorrhagicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Direct oral anticoagulant for acute coronary syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Direct oral anticoagulant for embolismPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Direct oral anticoagulant for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Direct oral anticoagulant for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxycycline for lymphatic abnormalitiesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
EA-230 90mg/kg/hour for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for arrhythmias, cardiacPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for cardiomyopathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EDG-15400 25 mg for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EDG-15400 50 mg for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EDIT-301 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Edwards EVOQUE System for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Edwards EVOQUE System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
efanesoctocog alfa (BIVV001) for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Electronic Cigarette and behavioural change support. for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Eloralintide for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for cardiomyopathy, hypertrophicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for heart defects, congenitalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Empagliflozin for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)13
Empagliflozin for heart failure, diastolicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for ventricular dysfunction, rightPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enavogliflozin for tricuspid valve insufficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Endocalyx Pro for hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ENDS (Vaporizer/e-cig) and smoking cessation counseling for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Enlicitide Decanoate for arteriosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Essential Pro Paclitaxel Drug-Eluting Balloon for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Evolocumab for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Evolocumab for coronary diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evolocumab for non-st elevated myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evolocumab for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exagamglogene autotemcel for anemia, sickle cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Exagamglogene autotemcel for beta-thalassemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Exercise for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Exerenibart for beta-thalassemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exploratory test group for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ferric derisomaltose for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fidanacogene Elaparvovec for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Fidanacogene Elaparvovec for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Finerenone for atrial fibrillationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fisetin for intermittent claudicationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fitusiran for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Fitusiran for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Fixed-Dose Combination Strategy for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Flecainide for heart arrestPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Flecainide for mitral valve prolapsePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
FOLFIRI + FOLFOX6/FOLFOX7 + S241656 + PANITUMUMAB + Cetuximab for histiocytosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Food Security Screening & Referral Program for cardiovascular diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Genicular artery embolization (GAE) for arterial occlusive diseasesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for primary myelofibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for thrombocythemia, essentialTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Goflikicept for pericarditisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for bone marrow failure disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Heart to Heart Yoga for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic stem-cell transplantation for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HiCM-188 therapy for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High dose CABG/LVAD+iPSC-CMs for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High dose Jia Shen Tablet for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High Dose LX2006 + Low dose LX2006 + Mid Dose LX2006 for cardiomyopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-resistance inspiratory muscle strength training for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
hiPSC-CM therapy for cardiomyopathy, dilatedPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
hiPSC-CM therapy for heart failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
HMB-002 (Part A) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 (Part B) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxycarbamide for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hyperpolarized 13C-pyruvate for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
IBI3016 for hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ibuprofen for ductus arteriosus, patentPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
iCM012 solution 2 mg/mL for reperfusion injuryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Iloprost for vaso-occlusive crisesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Imatinib Mesylate for hypereosinophilic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ime for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ime for prehypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immediate HSCT Group for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Impella 5.5 for shock, cardiogenicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inclisiran for acute coronary syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Inclisiran for non-st elevated myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Inclisiran for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Infliximab for aneurysmPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Infliximab for vasculitisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Innoventric Unica™ System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inspiratory muscle strength training for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inspiratory muscle strength training for prehypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inspiratory muscle training (IMT) for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intensified medical follow-up and glucose-lowering drugs for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intrepid™ TTVR System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Iron sucrose for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Isatuximab for anemia, aplasticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketoprofen for lymphedemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
L-PSGB first for tachycardia, ventricularTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
L-PSGB first for ventricular fibrillationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laplace TTVR System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Left main stenting with intravascular lithotripsy for atherosclerosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Left main stenting with intravascular lithotripsy for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lenalidomide for erdheim-chester diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lepodisiran for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lepodisiran Sodium for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lorundrostat for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
low dose CABG+iPSC-CMs for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Low dose Jia Shen Tablet for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Luspatercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Lusutrombopag combined with recombinant human thrombopoietin for thrombocytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LuxValve PLlus for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mandibular advancement Device for essential hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mandibular advancement Device for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mandibular advancement Device for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Maridebart Cafraglutide for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Marstacimab for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Marstacimab for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) for atrial fibrillationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Metformin ER for intermittent claudicationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin hydrochloride for heart failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Midodrine for hypotensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitapivat for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MitraClip System for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MitraClip System for mitral valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Momelotinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Muvalaplin for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Narrative Intervention for Chronic Illness-Heart Failure for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Navitoclax for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neovasc Reducer for angina pectorisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nevibolol for microvascular anginaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nicotine-Free Electronic Cigarette and behavioural change support. for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NightWare for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Nintedanib for telangiectasia, hereditary hemorrhagicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nk-dli for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NTLA-2001 for cardiomyopathiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Orforglipron for cardiovascular diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Orforglipron for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Pci for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Peginterferon α-2b injection for thrombocythemia, essentialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pelabresib for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pharmacogenetic algorithm for atrial fibrillationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pirfenidoneone for lymphedemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Empagliflozin for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Placebo + Lorundrostat for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Placebo + Orforglipron for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Polycap for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyCore (Polydextrin, L-Carnitine, D-xylitol) for heart failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for cardiovascular diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
PolyPill for heart diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for non-st elevated myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Polypill: Red Heart Pill for cardiovascular diseasesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Pozelimab + cemdisiran for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prasugrel for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prasugrel or Ticagrelor for acute coronary syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prasugrel or Ticagrelor for atrial fibrillationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pravastatin (drug) for lymphedemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton Total Marrow Irradiation for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Qidan Xiaoke Granules + Standard Medical Therapy for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ranolazine for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ranolazine for ventricular dysfunction, rightPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant Human Thymosin Beta 4 Injection (NL005) for anterior wall myocardial infarctionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant Human Thymosin Beta 4 Injection (NL005) for st elevation myocardial infarctionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Red Heart Pill 2b (Polypill) for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Regadenoson for coronary artery diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for cardiovascular diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for peripheral arterial diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rivaroxaban for venous thromboembolismPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for cytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Romiplostim for anemia, aplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Romiplostim for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROPEGINTERFERON ALFA-2B for thrombocythemia, essentialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rosuvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RP-A501 for cardiomyopathy, hypertrophicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
RP-A501 for hypertrophy, left ventricularPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib + NAVITOCLAX for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxoprubart for hemoglobinuria, paroxysmalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
S241656 for histiocytosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
S241656 + PEMBROLIZUMAB for histiocytosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
S241656 + Trametinib for histiocytosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacubitril-valsartan for heart failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SAL0140 for hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selnoflast for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for atrial fibrillationPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Silver diammine fluoride for heart arrestTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sirolimus for arteriovenous malformationsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sodium zirconium cyclosilicate for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sonrotoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SPK-8011QQ for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for factor vii deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
SR604 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for hemophilia bPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for von willebrand diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care (SOC) for lymphedemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tai Chi (CHI) for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tai Chi (CHI) for prehypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tasquinimod for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TASQUINIMOD + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tenecteplase for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tertinat for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tertinat for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Test group for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Thiamine Mononitrate 300 mg for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor for acute coronary syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)19
Ticagrelor for angina, stableTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor for angina, unstablePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Ticagrelor for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Ticagrelor for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor for non-st elevated myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Ticagrelor + Aspirin for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor + placebo for non-st elevated myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor + placebo for st elevation myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirzepatide for heart failure, systolicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tirzepatide for hypertensionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TNX-103 for heart failurePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TOCOPHEROL + Pentoxifylline for lymphedemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Topaz TTVR System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for erdheim-chester diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tranexamic acid for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter PDA Coil for ductus arteriosus, patentTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter tricuspid valve edge-to-edge repair for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter tricuspid valve edge-to-edge repair for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter Tricuspid Valve Intervention for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Transcatheter tricuspid valve replacement for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)6
Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter Tricuspid Valved Stent Graft for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Transvenous Tricuspid Valve System implantation + OMT for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRiCares Topaz TTVR System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tricuspid Valve Replacement System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tricuspid Valve Replacement System via jugular vein for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TricValve System for heart failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
trigagrelor for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Triple oral lipid lowering treatment for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TruGamma System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ULIXERTINIB + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Valsartan for heart failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VDyne Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Venetoclax + AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venous Excess Ultrasound (VEXUS)-Guided Management for hyperemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vericiguat for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VERVE-102 for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VERVE-102 for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
VERVE-102 for myocardial infarctionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Very-short DAPT less than 1 month after PCI for acute coronary syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Very-short DAPT less than 1 month after PCI for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vicadrostat for hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
vicadrostat / empagliflozin combination 1 for heart failurePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for cytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
YMI024 for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zemocimig for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ziltivekimab for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Ziltivekimab for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ziltivekimab for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zotarolimus-eluting stent (Endeavor Resolute) for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zovegalisib for klippel-trenaunay-weber syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zovegalisib for lymphatic abnormalitiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zovegalisib for vascular malformationsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1